The trusted source for
healthcare information and
Clinicians can use new monoclonal antibody therapies to treat high-risk patients presenting with mild to moderate COVID-19 symptoms. However, despite the promise to depress viral loads, logistical and other challenges continue to stand in the way of larger-scale use. Still, some EDs are trying the therapeutics, with promising results.
Financial Disclosure: None of the planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.